mCRPC update: Best practice and new insights
Live, virtual 60-minute roundtable
19 June 2024 – 15:00–16:00 UTC
Attend this roundtable to hear the latest on best practice mCRPC management and put questions to the expert faculty
- Approaches for non-continuous androgen-deprivation monotherapy (ADT) for mCRPC, such as intermittent ADT
- Non-androgen-deprivation approaches for mCRPC, with a focus on bone resorptive agents
- Systemic therapy for mCRPC, timing and sequencing
- Best-practice mCRPC symptom management, including radiation therapy and pain management
Professors Neeraj Agarwal, Axel Merseburger, Karim Fizazi, and Bárbara Vieira Lima Aguiar Melão will explore these topics, consider the potential impact of data presented at the 2024 ASCO Genitourinary Cancers Symposium and 2024 ASCO Annual Meeting, and highlight the in-progress trials to watch out for.
Not sure you can attend live? Register anyway and we’ll let you know when it becomes available to watch on demand.
Agenda
| mCRPC update: Best practice and new insights 19 June 2024 – 15:00–16:00 UTC |
|
| Chair: Neeraj Agarwal | |
| Welcome and introductions | Neeraj Agarwal |
| Androgen-deprivation therapy sparing for managing mCRPC | Axel Merseburger |
| Non-androgen-deprivation therapy approaches for managing mCRPC | Karim Fizazi |
| A case-based approach to treatment sequencing for mCRPC | Bárbara Vieira Lima Aguiar Melão |
| Best practice symptom management for mCRPC | Neeraj Agarwal |
| Live Q&A | All faculty |
| Takeaways and close | Neeraj Agarwal |
Register now for the mCRPC update: Best practice and new insights roundtable
Faculty
Professor Neeraj Agarwal
Professor Agarwal is a Professor of Medicine and a Presidential-Endowed Chair of cancer research at the Huntsman Cancer Institute (HCI), University of Utah, USA, where he also serves as Senior Director for Clinical Research. He also directs the HCI's Genitourinary Oncology Program and the Center of Investigational Therapeutics.
Disclosures: Consultancy to Astellas, AstraZeneca, AVEO, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Lilly, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seagen.
Research funding to institution (lifetime): Arvinas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, CRISPR Therapeutics, Eisai, EMD Serono, Exelixis, Genentech, Gilead, GSK, Immunomedics, Janssen, Lava, Lilly, Medivation, Merck, Nektar, Neoleukin, NewLink Genetics, Novartis, ORIC, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seagen, Takeda, Telix, and Tracon.
Professor Axel Merseburger
Professor Merseburger is Professor of Urology and chair of the Department of Urology at University Hospital Schleswig-Holstein, Germany. He is chair for the European Scholarship Program and a board member of the European Association of Urology. He is Editor-in-Chief of the European Journal of Haematology and Oncology and Aktuelle Urologie.
Disclosures: Lectures/speaker/honoraria: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ferring, Ipsen, Janssen, Merck Serono, MSD, Novartis, Pfizer, Recordati, Roche, Takeda, and Teva. Consultancy: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, EUSAPharm, Ferring, Ipsen, Janssen, Merck Serono, MSD, Novartis, Pfizer, Recordati, Roche, Takeda, and Teva. Research and clinical trials: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, EUSAPharm, Ipsen, Janssen, Merck Serono, MSD, Novartis, Pfizer, Recordati, Roche, Takeda, and Teva.
Professor Karim Fizazi
Professor Fizazi is a medical oncologist at Institut Gustave Roussy and Professor in Oncology at the Université Paris-Saclay, France. He is President of the French Groupe d’Etude des Tumeurs Genito-Urinaires (GETUG). Professor Fizazi is Associate Editor of the European Journal of Cancer.
Disclosures: Participation in advisory boards and talks for Amgen, Astellas, AstraZeneca, Bayer, Clovis, Daiichi Sankyo, Janssen, MSD, Novartis/AAA, Pfizer, and Sanofi. Honoraria go to Gustave Roussy. Participation in advisory boards with personal honorarium for Arvinas, CureVac, and Orion.
Professor Bárbara Vieira Lima Aguiar Melão
Professor Melão is Director of Oncology at the Adventist Hospital of Manaus, Brazil, and a member of the Brazilian Society of Urology (SBU). She is a PhD student at the Faculty of Medicine at the University of São Paulo.
Disclosures: Clinical trials: Janssen. Speaker: Aspen, Janssen.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.